Option chain shows key data for MSC Income Fund Inc Ordinary Shares's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for MSC Income Fund Inc Ordinary Shares.

MSC Income Fund Inc Ordinary Shares (OTC:MSCF) Stock, Option Chain

MSC Income Fund Inc Ordinary Shares

Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) has outperformed the market over the past 20 years by 3.91% on an annualized basis producing an average annual return of 12.3%. Currently, Alaska Air Gr has a market capitalization of $9.17 billion. 
Buying $1000 In ALK: If an investor had bought $1000 of ALK stock 20 years ago, it would be worth $10,191.84 today based on a price of $74.50 for ALK at the time of writing.
<h3>Alaska Air Gr's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738795512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Alaska Air Gr 20 Years Ago Would Be Worth This Much Today

Sangoma Technologies (TSX:<a class="ticker" href="https://www.benzinga.com/stock/STC#TSX">STC</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.03) by 100 percent. This is a 40 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $59.10 million which missed the analyst consensus estimate of $63.18 million by 6.46 percent. This is a 5.10 percent decrease over sales of $62.28 million the same period last year.

Earnings

Earnings Misses

TSX:STC

Sangoma Technologies Q2 EPS $(0.06) Misses $(0.03) Estimate, Sales $59.10M Miss $63.18M Estimate

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) annnounced its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/n43509453/viking-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-corpor">details from the report.&nbsp;</a>
The Details:&nbsp;Viking Therapeutics reported quarterly losses of&nbsp;32 cents&nbsp;per share, which missed the analyst consensus estimate for losses of 28 cents. The company reported losses of&nbsp;25 cents&nbsp;per share in the same period last year.
Viking reported a net loss of&nbsp;$35.4 million in the fourth quarter, compared to a net loss of&nbsp;$24.6 million, in the corresponding period in 2023.
Research and development expenses for the year ended Dec. 31, 2024, were $101.6 million compared to $63.8 million for the same period in 2023. The increase was primarily due to increased expenses related to manufacturing for drug candidates, stock-based compensation and salaries and benefits, partially offset by a decrease in expenses related to clinical studies and preclinical studies.
Read Next:<a href="https://www.benzinga.com/news/earnings/25/02/43512137/ford-shares-skid-after-q4-report-details"> Ford Shares Skid After Q4 Report: Details</a>
&#8220;2024 was an exciting and extremely productive year for Viking,&#8221; stated Brian Lian, Ph.D., CEO of Viking. 
&#8220;During the year, the company reported positive data from four different clinical trials, including results from the Phase 2 VENTURE study of subcutaneous VK2735 for obesity, the Phase 1 study of an oral tablet formulation of VK2735 for obesity, the Phase 2b VOYAGE study of VK2809 for the treatment of MASH and fibrosis, and the Phase 1b study of VK0214 for X-ALD. Each of these studies successfully achieved their objectives with each in our view demonstrating best-in-class data,&#8221; Lian said. 
VKTX Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Viking Therapeutics shares are down 8.72% after hours at $30.58 on Wednesday.&nbsp;&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/02/43468887/robert-f-kennedy-nomination-advances-to-full-senate-vaccine-stocks-drop">Robert F. Kennedy&#8217;s Health Secretary Nomination Advances To Full Senate: Vaccine Stocks Drop&nbsp;</a></li>
</ul>
Photo: T. Schneider via Shutterstock

Health Care

After-Hours Center

Movers

General

VKTX

Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates

McStarlite is a provider of complex sheet metal aerospace components. In its first year of ownership, the Company expects the acquisition to be accretive to its earnings. McStarlite Co. will be reported as part of Standex's Engineering Technologies Group business segment. In calendar year 2024, McStarlite revenue was approximately $33 million with an adjusted EBITDA margin above 20%.&nbsp;

Standex Acquires Privately-Held, California-Based McStarlite For $56.5M Cash

Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) is looking for Q1 Adj EPS of $0.06-0.11 vs $0.42 analyst estimate. sees sales of $70.000 million-73.000 million vs $92.91 million estimate.

Guidance

Impinj Sees Q1 Adj EPS $0.06-0.11 vs $0.42 Est; Sees Sales $70.000M-73.000M vs $92.91M Est

Gold production in 2025 reflects the following:
<ul>
<li>First production from Skouries in 2026 rather than 2025.</li>
<li>At Kisladag, expected production has been impacted by longer than planned leach cycles and lower grade stacked.</li>
<li>At Olympias, expected production has been impacted by a delay in mill expansion commissioning to 650ktpa, and unscheduled maintenance of the gold concentrate filters.</li>
</ul>
"Our updated 2025 gold production guidance is expected to be between 460,000 and 500,000 ounces. This has been lowered from our prior outlook provided in 2024 to reflect the change in initial production at Skouries from the third quarter of 2025 to the first quarter of 2026. In addition, guidance at both Kisladag and Olympias has been lowered compared to our prior 2025 guidance provided in 2024," the company said.&nbsp;

Eldorado Gold Updates 2025 Gold Production Guidance To 460,000 - 500,000 Ounces; Now Expects First Production At Skourie In Q1 Of 2026 Rather Than 2025

Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) reported quarterly earnings of $0.48 per share which met the analyst consensus estimate. This is a 433.33 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $91.57 million which missed the analyst consensus estimate of $92.95 million by 1.49 percent. This is a 29.61 percent increase over sales of $70.65 million the same period last year.

Impinj Q4 Adj $0.48, Inline, Sales $91.57M Miss $92.95M Estimate

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Trading Halt: Halted at 5:30:17 p.m. ET - Trading Halt: Halt News Pending

The Company announced in September 2024 that the signal-finding study met its primary endpoint. Next steps will be guided by regulatory discussions and on-going long term extension study.

RXRX

Recursion Reports 12 Month Data From Phase 2 Study (Sycamore) Of REC-994 At International Stroke Conference

The company reported net sales of $19.51 billion for the retail month of January, the four weeks ended February 2, 2025, an increase of 9.2 percent from $17.87 billion last year.
Net sales for the first 22 weeks were $113.55 billion, an increase of 8.2 percent from $104.94 billion last year.

COST

Reported Earlier, Costco Wholesale January Comparable Sales Up 7.5%

FormFactor Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) shares are diving in extended trading Wednesday after the company reported fourth-quarter financial results that came up short <a href="https://www.benzinga.com/pressreleases/25/02/g43509179/formfactor-inc-reports-2024-fourth-quarter-results">of analyst expectations</a>.
<ul>
<li>Q4 Revenue: $189.48 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $191.12 million</li>
</ul>
<ul>
<li>Q4 Adjusted EPS: 27 cents, versus estimates of 29 cents</li>
</ul>
Total revenue was up 12.7% on a year-over-year basis. FormFactor said High Bandwidth Memory grew fourfold in fiscal 2024 compared to the prior year, driven by adoption of generative AI. DRAM probe-card revenue&nbsp;continued to climb in the quarter, reaching record levels for the third straight quarter.
&#8220;As expected, FormFactor reported sequentially lower fourth-quarter revenue, gross margin, and non-GAAP earnings per share, driven by the forecasted reduction in Foundry &amp; Logic probe-card revenue,&#8221; said Mike Slessor, CEO of FormFactor. &#8220;This was partially offset by growth in DRAM probe-card revenue, with HBM increasing to approximately half of DRAM revenue.&#8221;
FormFactor also announced that the company and MBK Partners are acquiring FICT Limited from Advantage Partners. FormFactor will invest $60 million and receive a 20% minority stake and a seat on the company&#8217;s board. 
&#8220;FormFactor&#8217;s investment in FICT builds on our long-term collaboration with them as a supplier of the industry-leading, high-performance components we use in our advanced probe cards, and provides a platform for accelerated development of tomorrow&#8217;s test and packaging consumables,&#8221; Slessor added.
See Also: <a href="https://www.benzinga.com/news/earnings/25/02/43511849/strategy-q4-earnings-bitcoin-treasury-company-spends-205b-on-btc-shares-inch-higher-despite-revenue-miss">Strategy Q4 Earnings: Bitcoin Treasury Company Spends $20.5B On BTC, Shares Inch Higher Despite Revenue Miss</a>
Outlook: FormFactor expects first-quarter revenue to be in the range of $165 million to $175 million versus estimates of $195.81 million. The company anticipates first-quarter adjusted earnings of 3 cents to 11 cents per share, versus estimates of 33 cents per share. 
FormFactor noted it has continued to see &#8220;slow demand&#8221; in high-volume markets like client PCs and mobile handsets in the first quarter. Despite the slowing demand, the company anticipates an overall demand increase for its products throughout 2025.
FORM Price Action: FormFactor shares were down 22.81% after hours, trading at $31.74 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using AI from MidJourney.

FORM

FormFactor Stock Falls On Q4 Earnings Miss, Weak Guidance As 'Slow Demand' Continues In Q1

S&amp;P 500 constituent Lennar Corp is spinning off Millrose Properties in a transaction expected to be completed on Friday, February 7.&nbsp;
Following the spin-off, Lennar will remain in the S&amp;P 500, and Millrose Properties, which is more representative of the small cap market space, will be added to the S&amp;P SmallCap 600. Ironwood Pharmaceuticals is no longer representative of the small-cap market space.

IRWD

MRPw

Millrose Properties To Replace Ironwood Pharmaceuticals In S&P SmallCap 600, Effective Prior To  Opening Of Trading On February 10

Associated Capital Group Q4 EPS $0.20 Down From $0.76 YoY, Sales $5.15M Down From $5.64M YoY

Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has outperformed the market over the past 5 years by 11.31% on an annualized basis producing an average annual return of 23.81%. Currently, Apple has a market capitalization of $3.49 trillion. 
Buying $100 In AAPL: If an investor had bought $100 of AAPL stock 5 years ago, it would be worth $289.19 today based on a price of $232.23 for AAPL at the time of writing.
<h3>Apple's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738793813_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

MSC Income Fund Inc Ordinary Shares

MSC Income Fund Inc Ordinary Shares (MSCF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga